Skip to main content
Algernon Health Inc. logo

Algernon Health Inc. — Investor Relations & Filings

Ticker · AGN ISIN · CA3978841078 CSE Human health and social work activities
Open in API
Filings indexed 579 across all filing types
Latest filing 2021-04-30 Regulatory Filings
Country CA Canada
Listing CSE AGN

About Algernon Health Inc.

https://www.algernonhealth.com/

Algernon Health Inc. is a healthcare company focused on the provision of advanced diagnostic services, primarily through the establishment of medical clinics specializing in Alzheimer's disease. A key offering is the utilization of brain-optimized Positron Emission Tomography (PET) scanning technology for screening and imaging within a planned network of North American facilities. The company maintains a clinical-stage drug development and repurposing division, which investigates existing, approved drugs for new therapeutic applications targeting unmet global medical needs.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer, signed by the CEO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2021. It is a certification letter rather than the interim report itself, and it explicitly states it is a certification under National Instrument 52-109. The document length is short (3142 characters) and contains no actual financial data or substantive financial analysis, only the certification statement. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR) itself.
2021-04-30 English
Interim MD&A - English.pdf
Regulatory Filings
2021-04-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-04-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Algernon Pharmaceuticals announcing that it has filed an end of Phase 2 meeting request (EOP2) with the FDA related to its COVID-19 clinical trial. It discusses regulatory interaction and clinical trial progress but does not contain any financial data, earnings results, or detailed report content. The document is short (4053 characters) and serves as an update on regulatory and clinical trial status rather than a financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial data. It is also not a certification or voting result. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-04-26 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Steven L. Wolf as a consultant for Algernon Pharmaceuticals' clinical research program. It focuses on management and scientific advisory changes rather than financial results, regulatory filings, or shareholder information. There is no indication of financial data, voting results, or report publication. The content fits best under Board/Management Information (MANG) as it announces a significant change in the company's advisory team relevant to management and clinical research guidance.
2021-04-07 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing topline data from a Phase 2b clinical trial conducted by Algernon Pharmaceuticals. It provides summary results and key findings from the trial but does not contain detailed financial statements, comprehensive analysis, or full report data. The document is relatively short (5917 characters) and serves as an initial announcement of clinical trial results rather than a full report or detailed presentation. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification. The content is best classified as a Capital/Financing Update (CAP) because it relates to clinical trial progress and potential future regulatory discussions, which are material updates relevant to investors and capital markets. Therefore, the most appropriate classification is CAP with high confidence.
2021-03-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.